FIGURE

Fig. 1

ID

ZDB-FIG-210729-37

Publication

Guha et al., 2021 - Combinatorial glucose, nicotinic acid, and N-acetylcysteine therapy has synergistic effect in preclinical C. elegans and zebrafish models of mitochondrial complex I disease

Other Figures

All Figure Page

Back to All Figure Page

Fig. 1

Schematic overview of experimental validation of combinatorial therapies in C. elegans and zebrafish models of respiratory chain complex I disease. Having previously identified 37 individual compounds in three major drug classes that significantly improved the short lifespan of complex I-deficient gas-1(fc21) mutant (that has a homozygous missense mutation in the nuclear-encoded complex I structural subunit NDUFS2 orthologue) C. elegans (worms) (Supplementary Material, Fig. S1), 11 combinations were randomly selected to evaluate the efficacy, toxicity and synergy of combining treatment classes on gas-1(fc21) worms’ lifespan as a primary outcome. Mechanistic analyses were performed at the level of mitochondrial physiology, transcriptome and metabolome analyses to interrogate the lead synergistic combination (glucose (Glu) + nicotinic acid (NAC) + N-acetylcysteine (NAC)). Validation of this lead combinatorial therapy was performed to assess brain death, swimming activity and effects on central biochemical readouts of mitochondrial dysfunction in a vertebrate zebrafish model of mitochondrial respiratory chain disease caused by pharmacologic (rotenone) inhibition of complex I function.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Hum. Mol. Genet.